Source: Annual Congress 2012 - Exhaled biomarkers in airway diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Boots, R. Schins, R. Godschalk, C. Albrecht, J. Dallinga, A. Bast, F. Schleich, M. Drent, F. J. van Schooten (Maastricht, Netherlands; Düsseldorf, Germany). Volatile organic compounds may provide a new and promising tool for diagnosing interstitial lung diseases. Eur Respir J 2012; 40: Suppl. 56, 2218

Member's Comments

No comment yet.

Related content which might interest you: A systematic review of the diagnostic accuracy of volatile organic compounds in airway diseases and their relation to markers of type-2 inflammation Source: ERJ Open Res, 7 (3) 00030-2021; 10.1183/23120541.00030-2021 Year: 2021 Multiple detectable exhaled volatile organic compounds (vocs) may serve as potential inflammatory biomarkers in COPD Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009 Integrating monitoring of volatile organic compounds (VOCs) in asthma and COPD into the routine lung function Source: International Congress 2015 – The next generation of lung function tests Year: 2015 A new possibility of process monitoring in lung cancer: Volatile organic compounds detected with ion mobility spectrometry to follow the success of the therapeutic process Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011 Interpretation of exhaled volatile organic compounds Source: Eur Respir Monogr 2010; 49: 115-129 Year: 2010 Non-targeted integrative multi-omics approaches on sputum reveal potential diagnostic and monitoring biomarkers for respiratory diseases Source: International Congress 2017 – Novel molecular and genetic targets in COPD Year: 2017 Volatile organic compound breath signatures of children with cystic fibrosis by real-time SESI-HRMS Source: ERJ Open Res, 6 (1) 00171-2019; 10.1183/23120541.00171-2019 Year: 2020 Diagnostic potential of organic halides as breath biomarkers in cystic fibrosis Source: Annual Congress 2007 - Clinical outcome studies and technical aspects of paediatric lung function testing Year: 2007 A case of occupational interstitial disease: when to invade the lungs and when non-invasive diagnostic investigations may be useful Source: International Congress 2019 – Occupational and epidemiology Grand Round Year: 2019 Volatile organic compounds in COPD: Is hexanal an inflammation biomarker? Source: International Congress 2016 – The future of lung function is beginning now Year: 2016 Evaluation of recently validated non-invasive formula using basic lung functions as a new screening tool for pulmonary hypertension in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009 Value of exhaled volatile organic compounds in monitoring airway disease Source: School Course 2013 - Monitoring of asthma, COPD and other airway diseases Year: 2013 Exhaled volatile organic compounds for better asthma control: could it be a future noninvasive adherence test? Source: Eur Respir J, 55 (2) 1902112; 10.1183/13993003.02112-2019 Year: 2020 Exhaled breath analysis by use of eNose technology: a novel diagnostic tool for interstitial lung disease Source: Eur Respir J, 57 (1) 2002042; 10.1183/13993003.02042-2020 Year: 2021 Interference RNA as a new tool and possible future therapy for inflammatory lung disease Source: Lung Science Conference 2005 - Evidence-based medicine for respiratory disease with special emphasis on inflammatory processes Year: 2005 Exhaled volatile organic compounds in idiopathic pulmonary fibrosis and disease progression Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis Year: 2020